AirSculpt Technologies (AIRS) Earnings Date & Reports

Key Takeaways

• AirSculpt Technologies (AIRS) is scheduled to report results for the third quarter of fiscal 2026 (the period ended September 30, 2026) in early November.
• Management has guided to a single-digit comparable revenue decline in Q3, excluding London center sales from the prior year, as softer consumer demand trends persisted into July.
• The company enters the quarter after two consecutive periods of stable revenue and positive same-center case growth, a meaningful turnaround from 2025's double-digit declines.
• Full-year 2026 revenue is expected at the lower end of the $151 million to $157 million range, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance was narrowed to $12 million to $14 million.
• Investors will focus on case volume, average selling price, customer acquisition costs, and early traction in new procedures aimed at patients using GLP-1 weight-loss medications.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Discover automated trading strategies with Trending AI Robots to help identify market opportunities.

Earnings Context and Why It Matters

AirSculpt Technologies, a national provider of premium, minimally invasive body contouring procedures, is navigating a turnaround in a challenging consumer spending environment. After same-center sales fell more than 20% in early 2025, the company has stabilized its revenue base and returned to positive case growth over the past two quarters. This upcoming report matters because it will test whether that stabilization can hold against choppy demand and rising marketing investment. For investors, Q3 results offer a read on the company's expanding procedure portfolio, its strategy to capture patients using GLP-1 (glucagon-like peptide-1) weight-loss drugs, and its progress toward sustained profitable growth after an extended period of revenue declines and net losses.

Earnings Expectations

AirSculpt has not issued formal quarterly earnings-per-share guidance, but management offered directional commentary during its second-quarter call. On a comparable basis, excluding London center sales from 2025, the company expects third-quarter revenue to decline in the single digits year over year, followed by an anticipated return to growth in the fourth quarter as new service offerings and marketing efforts ramp.

For the full fiscal year 2026, management reaffirmed revenue at the lower end of its $151 million to $157 million range and lowered its adjusted EBITDA outlook to $12 million to $14 million, reflecting roughly $5 million in additional intentional marketing investment. By comparison, second-quarter revenue was $42.9 million (down 2.5% year over year), with adjusted EBITDA of $4.9 million and a net loss of $1.1 million. Key operating metrics to watch include case volume (which grew 1% year over year in Q2), average selling price (approximately $12,700), and customer acquisition cost, which rose to about $3,500 per case as the company ramped brand marketing.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for those monitoring names like AirSculpt Technologies ahead of key catalysts. Explore the AI Screener to build watchlists and surface actionable ideas aligned with your strategy.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but stabilizing. AirSculpt shares have benefited from the company's improving revenue trajectory and debt-reduction efforts, yet management's acknowledgment that sales trends softened in June and into July has tempered near-term expectations. The narrowed EBITDA guidance signals that margin pressure from marketing investment will persist in the near term, even as gross margins remain healthy at roughly 61% of revenue. Key risk factors include further weakening in discretionary consumer spending, elevated customer acquisition costs, and execution risk around newer procedures such as skin excision, mastopexy, and the recently announced AlloClae partnership. How the stock reacts will likely hinge on whether case volume momentum continues and whether management reaffirms its fourth-quarter growth expectations.

Forward Outlook and Key Factors to Monitor

Beyond the Q3 headline numbers, investors should track several forward-looking themes. The company's push to serve patients using GLP-1 weight-loss medications remains its most significant long-term opportunity. Management estimates nearly 19 million potential patients may be interested in body contouring or related aesthetic procedures, and its expanded service portfolio could represent more than $100 million in long-term revenue across the existing center base.

Marketing efficiency is a second critical factor. Customer acquisition cost has risen to roughly $3,500 per case, and management is refining its approach to GLP-1 patient outreach while adapting to changes in search-engine behavior. Whether that investment translates into higher conversion and case volume will shape profitability through 2026 and beyond.

Finally, balance-sheet discipline and liquidity remain in focus. The company reduced gross debt by more than $30 million since the start of 2025, extended its term loan maturity to November 2027, and ended Q2 with roughly $24 million in total liquidity. Guidance does not yet assume contributions from newer offerings or new center openings, leaving room for upside if execution improves—but also underscoring the near-term reliance on stabilizing the existing center base.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations